R&D From genetic insight to Phase 3: What rare neurology require... Rare neurology is not defined by a lack of scientific opportunity or capital.
Events Partner Content Welcome to 1st Rare & Genetic Neurodegenerative Drug Dev... Developing R&G neurodegenerative therapies
Oncology ASCO 2026: Three ADC approvals in five days, with Ken Keller... At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
